Evidence map›Paper›PMID 41113540›Full record

ReviewUS cardiology2025

Role of Device Therapy in Complementing Contemporary Medical Management.

Yoel Benarroch, Natalie Tapaskar, Amin Yehya

Abstract readReview
In one paragraph

Review in US cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yoel BenarrochInternal Medicine, Beth Israel Deaconess Medical Center Boston, MA.ORCID https://orcid.org/0000-0001-6978-4518
Natalie TapaskarCardiology, UT Southwestern Medical Center Dallas, TX.ORCID https://orcid.org/0000-0002-2054-1926
Amin YehyaAdvanced Heart Failure Center, Sentara Heart Hospital Norfolk, VA.ORCID https://orcid.org/0000-0001-5947-4778

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a clinical syndrome characterized by signs and symptoms resulting from any structural or functional deficiency of ventricular filling or blood ejection. The mainstay of initial treatment remains lifestyle modifications, guideline-directed medical therapy, and addressing contributing factors. However, the past two decades have come with significant advances in device therapies to improve morbidity and mortality in HF despite evidence-based management as above. Given the rapidly evolving area of HF research and therapeutic development, it is important for clinicians to be familiar with novel therapies and how they can complement medical management. In this review we discuss the current landscape of novel non-surgical device therapies in HF, their respective trials, major outcomes, and their mechanisms of action and target pathways.

Indexed as

autonomic modulatorsclinical trialsdevice therapyHeart failurepressure sensor monitoring devicesvalvular disease

Identifiers

PMID41113540
PMCPMC12532167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.